Trends and future developments in the pharmacological treatment of acute ischaemic stroke

Drugs

Volumn 54, Issue 1, 1997, Pages 9-38

  Del Zoppo, Gregory J ^a   Wagner, Simone ^a   Tagaya, Masafumi ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; 6,7 DICHLORO 5 NITRO 2,3 QUINOXALINEDIONE; ADENOSINE RECEPTOR STIMULATING AGENT; AMPA RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BARBITURIC ACID DERIVATIVE; BASIC FIBROBLAST GROWTH FACTOR; CALCIUM CHANNEL BLOCKING AGENT; CITICOLINE; CORTICOSTEROID; FIBRINOLYTIC AGENT; FREE RADICAL; GANGLIOSIDE; GLYCEROL; IMMUNOSUPPRESSIVE AGENT; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LUBELUZOLE; MONOCLONAL ANTIBODY; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NALOXONE; NITRIC OXIDE SYNTHASE INHIBITOR; NIZOFENONE; PENTOXIFYLLINE; PLASMINOGEN ACTIVATOR; SCAVENGER; TIRILAZAD; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTERY OCCLUSION; BLEEDING; BLOOD CLOT LYSIS; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CAUSE OF DEATH; CLINICAL TRIAL; COMPLEMENT ACTIVATION; DRUG EFFICACY; ECONOMIC ASPECT; FIBRINOLYSIS; HUMAN; HYPOTHERMIA; IMMUNOMODULATION; INFLAMMATION; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NEUROPROTECTION; NONHUMAN; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHYSICAL DISABILITY; RECANALIZATION; REPERFUSION; REVIEW; STROKE; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL; THROMBUS; TREATMENT PLANNING;

THROMBUS;

EID: 0030820663     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199754010-00002     Document Type: Review

References (344)

1. Astrup J, Siesjö BK, Symon L. Thresholds in cerebral ischemia - the ischemic penumbra, Stroke 1981; 12 (6): 723-5
2. Lassen NA. Pathophysiology of brain ischemia as it relates to the therapy of acute ischemic stroke. Clin Neuropharmacol 1990; 13: S1-8
3. Siesjö BK. Pathophysiology and treatment of focal cerebral ischemia: Part I. Pathophysiology. J Neurosurg 1992; 77: 169-84
4. Siesjö BK. Pathophysiology and treatment of local cerebral ischemia: Part II. Mechanisms of damage and treatment. J Neurosurg 1992; 77: 337-54
5. Solis OJ, Roberson GR, Taveras JM, et al. Cerebral angiography in acute cerebral infarction. Rev Interam Radiol 1977; 2: 19-25
6. Mori E. Fibrinolytic recanalization therapy in acute cerebrovascular thromboembolism. In: Hacke W, del Zoppo GJ, Hirschberg M, editors. Thrombolytic therapy in acute ischemic stroke. Heidelberg: Springer-Verlag, 1991: 137-46
7. del Zoppo GJ, Poeck K, Pessin MS, et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 1992; 32: 78-86
8. Mori E, Yoneda Y, Tabuchi M, et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992; 42: 976-82
9. von Kummer R, Hacke W. Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery. Stroke 1992; 23: 646-52
10. Bachmann F, Kruithof IEKO. Tissue plasminogen activator: chemical and physiological aspects. Semin Thromb Hemost 1984; 10: 6-17
11. Aoki N, Harpel PC. Inhibitors of the fibrinolytic enzyme system. Semin Thromb Hemost 1984; 10: 24-41
12. Collen D, Lijnen HR. New approaches to thrombolytic therapy. Arteriosclerosis 1984; 4: 579-85
13. Verstraete M, Collen D. Thrombolytic therapy in the eighties. Blood 1986; 67: 1529-41
14. Kakkar VV, Scully MF. Thrombolytic therapy. Br Med Bull 1978; 34: 191-9
15. Sharma GVRK, Cella G, Parish AF, et al. Drug therapy: thrombolytic therapy. N Engl J Med 1982; 306: 1268-76
16. Verstraete M. Biochemical and clinical aspects of thrombolysis. Semin Hematol 1978; 15: 35-54
17. Plow EF, Felez J, Miles LA. Cellular regulation of fibrinolysis. Thromb Haemost 1991; 66: 132-6
18. Castellino FJ. Biochemistry of human plasminogen. Semin Thromb Hemost 1984; 10: 18-23
19. Pizzo SV, Petruska DB, Doman KA, et al. Releasable vascular plasminogen activator and thrombotic strokes. Am J Med 1985; 79: 407-11
20. Gaffrey PJ, Lane DA, Kakkar VV, et al. Characterization of a soluble D-dimer-E complex in cross-linked fibrin digests. Thromb Res 1975; 7: 89-99
21. Forsgren M, Raden B, Israelsson M, et al. Molecular cloning and characterization of a full-length cDNA clone for human plasminogen. FEBS Lett 1987; 213: 254-60
22. Bachmann F. Molecular aspects of plasminogen, plasminogen activators and plasmin. In: Bloom AL, Forbes CD, Thomas DP, et al., editors. Haemostasis and thrombosis. Edinburgh: Churchill Livingstone, 1994: 575-613
23. Johnson AJ, Tillett WS. Lysis in rabbits of intravascular blood clots by the streptococcal fibrinolytic system (streptokinase). J Exp Med 1952; 95: 449-64
24. Robbins KC, Summaria L, Hsieh B, et al. The peptide chains of human plasmin. J Biochem 1967; 242: 2333-42
25. Robbins KC. The plasminogen-plasmin system. In: Comerota AJ, editor. Thrombolytic therapy for peripheral vascular disease. Philadelphia: J.B. Lippincott, 1995: 41-65
26. Thorsen S, Mullertz S, Svenson E, et al. Sequence of formation of molecular forms of plasminogen and plasminogen-inhihitor complexes in plasma activated by urokinase or tissue-type plasminogen activator. Biochem J 1984; 223: 179-87
27. Hoylaerts M, Rijken DC, Lijnen HR, et al. Kinetics of the activation of plasminogen by human tissue plasminogen activator: role of fibrin. J Biol Chem 1982; 257: 2912-9
28. Collen D. On the regulation and control of fibrinolysis. Thromb Haemost 1980; 43: 77-89
29. Wun T-C, Capugno A. Initiation and regulation of fibrinolysis in human plasma at the plasminogen activator level. Blood 1987; 69: 1354-62
30. Rijken DC. Structure/function relationships of t-PA. In: Kluft C, editor. Tissue Type Plasminogen Activator (t-PA): physiological and clinical aspects. Vol. 1. Boca Raton (FL): CRC Press, 1988: 101-22
31. Jörnvall H, Pohl G, Bergsdorf N, et al. Differential proteolysis and evidence for a residue exchange in tissue plasminogen activator suggest possible association between two types of protein microheterogeneity. FEBS Lett 1983; 156: 47-50
32. Pennica D, Holmes WE, Kohr WJ, et al. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature 1983; 301: 214-21
33. Ehrlich HJ, Bang NW, Little SP, et al. Biological properties of a kringleless tissue plasminogen activator (t-PA) mutant. Fibrinolysis 1987; 1: 75-81
34. White FW, Barlow GH, Mozen MM. The isolation and characterization of plasminogen activators (urokinase) from human urine. Biochemistry 1966; 5: 2160-9
35. Lovett DH, Ryan JL, Sterzel RB. Stimulation of rat mesangial wall proliferation by macrophage interleukin-1. J Immunol 1983; 65: 713-31
36. Fletcher AP, Alkjaersig N, Sherry S, et al. The development of urokinase as a thrombolytic agent: maintenance of a sustained thrombolytic state in man by its intravenous infusion. J Lab Clin Med 1965; 65: 713-31
37. Stump DC, Mann KH. Mechanisms of thrombus formation and lysis. Ann Emerg Med 1988; 17: 1138-47
38. Davies MC, Englert ME, De Rezo EC. Interaction of streptokinase and human plasminogen observed in the ultracentrifuge under a variety of experimental conditions. J Biol Chem 1964; 239 (8): 2651-6
39. Reddy KN, Marcus B. Mechanisms of activation of human plasminogen by streptokinase. J Biol Chem 1972; 246: 1683-91
40. Fletcher AP, Alkjaersig N, Sherry S. The clearance of heterologous proteins from the circulation of normal and immunized man. J Clin Invest 1958; 37 (9): 1306-15
41. Standing R, Fears R, Ferres H. The protective effect of acylation on the stability of APSAC (Eminase) in human plasma [abstract]. Fibrinolysis 1988; 2: 157
42. Ferres H. Preclinical pharmacological evaluation of Eminase (APSAC). Drugs 1987; 33 Suppl. 3: 33-50
43. Lack CH. Streptokinase: an activator of plasma protease. Nature 1948; 161: 559-60
44. Lignen HR, de Cock F, Matsuo O, et al. Comparative fibrinolytic and fibrinogenolytic properties of staphylokinase and streptokinase in plasma of different species in vitro. Fibrinolysis 1992; 6: 33-7
45. 2-antiplasmin and fibrin. Biochim Biophys Acta 1992; 1118: 144-8
46. Witt W, Maass B, Baldus B, et al. Coronary thrombosis with Desmodus salivary plasminogen activator in dogs: fast and persistent recanalization by intravenous bolus administration. Circulation 1994; 90: 421-6
47. Hare TR, Gardell SJ. Vampire bat salivary plasminogen activator promotes robust lysis of plasma clots in a plasma milieu without causing fluid phase plasminogen activation. Thromb Haemost 1992; 68: 165-9
48. Bergum PW, Gardell SJ. Vampire bat salivary plasminogen activator exhibits a strict and fastidious requirement for polymeric fibrin as its cofactor, unlike human tissue-type plasminogen activator: a kinetic analysis. J Biol Chem 1992; 267: 17726-31
49. Witt W, Baldus B, Bringmann P, et al. Thrombolytic properties of Desmodus rotundus (vampire bat) salivary plasminogen activator in experimental pulmonary embolism in rats. Blood 1992; 79: 1213-7
50. Mellot MJ, Stabilito II, Holahan MA, et al. Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombosis. Arterioscler Thromb 1992; 12: 212-21
51. Philips M, Juul AG, Thorsen S. Human endothelial cells produce a plasminogen activator inhibitor and a tissue-type plasminogen activator-inhibitor complex. Biochim Biophys Acta 1984; 802: 99-110
52. Loskutoff DJ, van Mourik JA, Erickson LA, et al. Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc Natl Acad Sci USA 1983; 80: 2956-60
53. Thorsen S, Philips M, Selmer J, et al. Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2. Eur J Biochem 1988; 175: 33-9
54. Stump D, Thienpoint M, Collén D. Purification and characterization of a novel inhibitor of urokinase from human urine: quantitation and preliminary characterization in plasma. J Biol Chem 1986; 261: 12759-66
55. Heeb MJ, Espana F, Geiger M, et al. Immunological identity of heparin-dependent plasma and urinary protein C inhibitor and plasminogen activator inhibitor-3. J Biol Chem 1987; 262: 15813-6
56. Linjen HR, Hoylaerts M, Collén D. Isolation and characterization of a human plasma protein with affinity for the lysine binding sites in plasminogen: role in the regulation of fibrinolysis and identification as histidine-rich glycoprotein. J Biol Chem 1980; 255: 10214-22
57. Bachmann F. Fibrinolysis. In: Verstraete M, Vermylen J, Lijnen HR, et al., editors. Thrombosis and haemostasis. Leuven: ISTH/University of Leuven Press, 1987: 227-65
58. Agnelli G, Buchanan MR, Fernandez F, et al. A comparison of the thrombolytic and hemorrhagic effects of tissue-type plasminogen activator and streptokinase in rabbits. Circulation 1985; 72: 178-82
59. Marder VJ, Shortell CK, Fitzpatrick PG, et al. An animal model of fibrinolytic bleeding based on the rebleed phenomenon: application to a study of vulnerability of hemostatic plugs of different age. Thromb Res 1992; 67 (1): 31-40
60. Loscalzo J, Vaughan DB. Tissue plasminogen activator promotes platelet disaggregation in plasma. J Clin Invest 1987; 79: 1749-55
61. Aldrich MS, Sherman SA, Greenberg HS. Cerebrovascular complications of streptokinase infusion. JAMA 1985; 253: 1777-9
62. del Zoppo GJ, Zeumer H, Harker LA. Thrombolytic therapy in acute stroke: possibilities and hazards. Stroke 1986; 17: 595-607
63. Okada Y, Yamaguchi T, Minematsu K, et al. Hemorrhagic transformation in cerebral embolism. Stroke 1989; 20: 598-603
64. Yamaguchi T, Minematsu K, Choki J, et al. Clinical and neuroradiological analysis of thrombotic and embolic cerebral infarction. Jpn Circ J 1984; 48: 50-8
65. Pessin MS, del Zoppo GJ, Estol CJ. Thrombolytic agents in the treatment of stroke. Clin Neuropharmacol 1990; 13: 271-89
66. Drake ME, Shin C. Conversion of ischemic to hemorrhagic infarction by anticoagulant administration: report of two cases with evidence from serial computed tomographic brain scans. Arch Neurol 1983; 40: 44-6
67. Meyer JS, Gilroy J, Barnhart MI, et al. Therapeutic thrombolysis in cerebral thromboembolism. Neurology 1963; 13: 927-37
68. Babikian VL, Kase CS, Pessin MS, et al. Intracerebral hemorrhage in stroke patients anticoagulated with heparin. Stroke 1989; 29: 1500-3
69. Furlan AJ, Cavalier SJ, Hobbs RE, et al. Hemorrhage and anticoagulation after nonseptic embolic brain infarction. Neurology 1982; 32: 280-2
70. Koller RL. Recurrent embolic cerebral infarction and anticoagulation. Neurology 1982; 32: 283-5
71. Donnan GA, Davis SM, Chambers BR, et al. Streptokinase for acute ischemic stroke with relationship to time of administration. JAMA 1996; 276: 961-6
72. Multicenter Acute Stroke Trial - Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 1996; 335: 145-50
73. Zeumer H, Freitag HJ, Grzyka U, et al. Local intra-arterial fibrinolysis in acute vertebrobasilar occlusion: technical developments and recent results. Neuroradiology 1989; 31: 336-40
74. Zeumer H. Survey of progress: vascular recanalizng techniques in interventional neuroradiology. J Neurol 1985; 231: 287-94
75. del Zoppo GJ, Ferbert A, Otis S, et al. Local intra-arterial fibrinolytic therapy in acute carotid territory stroke: a pilot study. Stroke 1988; 19: 307-13
76. Mori E, Tabuchi M, Yoshida T, et al. Intracarotid urokinase with thromboembolic occlusion of the middle cerebral artery. Stroke 1988; 19: 802-12
77. Theron J, Courtheoux P, Casaseo A, et al. Local intra-arterial fibrinolysis in the carotid territory. AJNR 1989; 10: 753-65
78. Matsumoto K, Satoh K. Topical intraarterial urokinase infusion for acute stroke. In: Hacke W, del Zoppo GJ, Hirschberg M, editors. Thrombolytic therapy in acute ischemic stroke. Heidelberg: Springer-Verlag, 1991: 207-12
79. Hacke W, Zeumer H, Ferbert A, et al. Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease. Stroke 1988; 19: 1216-22
80. Möbius E, Berg-Dammer E, Kühne D, et al. Local thrombolytic therapy in acute basilar artery occlusion: experience with 18 patients. In: Hacke W, del Zoppo GJ, Hirschberg M, editors. Thrombolytic therapy in acute ischemic stroke. Heidelberg: Springer-Verlag, 1991: 213-5
81. Freitag H-J, Zeumer H, Knospe V. Acute central retinal artery occlusion and the role of thrombolysis. In: del Zoppo GJ, Mori E, Hacke W, editors. Thrombolytic therapy in acute ischemic stroke II. Heidelberg: Springer-Verlag, 1993: 103-5
82. Zeumer H, Freitag H-J, Zarella F, et al. Local intra-arterial fibrinolytic therapy in patients with stroke: urokinase vs recombinant tissue plasminogen activator (rt-PA). Neuroradiology 1993; 35: 159-62
83. Ohtaki M, Shinya T, Yamamura A, et al. Local fibrinolytic therapy using superselective catheterization for patients with acute cerebral embolism within 10 hours. In: Tomita M, Mchedlishvili A, Rosenblum W, et al., editors. Microcirculatory stasis in the brain. Amsterdam: Elsevier Science Publishers, 1993: 539-45
84. Higashida RT, Halbach VV, Barnwell SL, et al. Thrombolytic therapy in acute stroke. J Endovasc Surg 1994; 1: 4-15
85. Barnwell SL, Clark WM, Nguyen TT, et al. Safety and efficacy of delayed intraarterial urokinase therapy with mechanical clot disruption for thromboembolic stroke. AJNR 1994; 15: 1817-22
86. Jansen O, von Kummer R, Forsting M, et al. Thrombolytic therapy in acute occlusion of the intracramal internal carotid artery bifurcation. AJNR 1995; 16: 1977-86
87. del Zoppo GJ, Higashida RT, Furlan AJ, et al. The Prolyse in Acute Cerebral Thromboembolism Trial (PROACT): results of 6 mg dose tier [abstract]. Stroke 1996; 27: 164
88. Mori E, Yoneda Y, Ohkawa S, et al. Double-blind placebo-controlled trial of intravenous recombinant tissue plasminogen activator (rt-PA) in acute carol id stroke [abstract]. Neurology 1991; 41 Suppl. 1: 347
89. von Kummer R, Forsting M, Sartor K, et al. Intravenous recombinant tissue plasminogen activator in acute stroke. In: Hacke W, del Zoppo GJ, Hirschberg M, editors. Thrombolytic therapy in acute ischemic stroke. Heidelberg: Springer-Verlag, 1991: 161-7
90. Yamaguchi T. Intravenous rt-PA in acute embolic stroke. In: Hacke W, del Zoppo GJ, Hirschberg M, editors. Thrombolytic therapy in acute ischemic stroke. Heidelberg: Springer-Verlag, 1991: 168-74
91. Yamaguchi T. Intravenous tissue plasminogen activator in acute thromboembolic stroke: a placebo-controlled, double-blind trial. In: del Zoppo GJ, Mori E, Hacke W, editors. Thrombolytic therapy in acute ischemic stroke II. Heidelberg: Springer-Verlag, 1993: 59-65
92. Yamaguchi T, Kikuchi H, Hayakawa T, et al. Clinical efficacy and safety of intravenous tissue plasminogen activator in acute embolic stroke: a randomized, double-blind, dose-comparison study of duteplase. In: Yamaguchi T, Mori E, Minematsu K, et al., editors. Thrombolysis in acute ischemic stroke III. Tokyo: Springer-Verlag, 1995: 223-9
93. Yamaguchi T, Hayakawa T, Kiuchi H. Intravenous tissue plasminogen activator ameliorates the outcome of hyperacute embolic stroke. Cerebrovasc Dis 1993; 3: 269-72
94. Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 1995; 346: 1509-14
95. Tognoni G, Roncaglioni MC. Dissent: an alternative interpretation of MAST-I [letter]. Lancet 1995; 346: 1515
96. Gruppo Italiano per Io Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397-401
97. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). GISSI-2: a factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990; 336: 65-71
98. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274: 1017-25
99. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-7
100. del Zoppo GJ. Acute stroke on the threshold of a therapy? [editorial]. N Engl J Med 1995; 333: 1632-3
101. Kwaan HC. Thromboembolic disorders of the eye. In: Comerota AC, editor. Thrombolytic therapy. Orlando: Grune and Stratton, 1988: 153-63
102. Schmidt D, Schumacher M, Wakhloo AK. Microcatheter urokinase infusion in central retinal artery occlusion. Am J Ophthalmol 1992; 113: 429-34
103. del Zoppo G, Yu J-Q, Copeland BR, et al. Tissue factor location in non-human primate cerebral tissue. Thromb Haemost 1992; 68: 642-7
104. Thomas WS, Mori E, Copeland BR, et al. Tissue factor contributes to microvascular defects following cerebral ischemia. Stroke 1993; 24: 847-53
105. Okada Y, Copeland BR, Fitridge R, et al. Fibrin contributes to microvascular obstructions and parenchymal changes during early focal cerebral ischemia and reperfusion. Stroke 1994; 25: 1847-54
106. Petersen P, Boysen G, Godifredsen J, et al. Placebo-controlled randomized trial of warfarin and aspirin to prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK Study. Lancet 1989; 1: 175-9
107. Stroke Prevention in Atrial Fibrillation Study Group Investigators. Preliminary report of the stroke prevention in atrial fibrillation study. N Engl J Med 1990; 322: 863-8
108. Boston Area Anticoagulation Trial/Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505-11
109. Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) study. J Am Coll Cardiol 1991; 18: 349-55
110. Kay R, Wong KA, Yu YL, et al. Low-molecular weight heparin in the treatment of acute ischemic stroke. N Engl J Med 1995; 333: 1588-93
111. Okada Y, Copeland BR, Mori E, et al. P-selectin and intercellular adhesion molecule-1 expression after focal brain ischemia and reperfusion. Stroke 1994; 25: 202-11
112. UK-TIA Study Group. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. BMJ 1988; 1: 316-20
113. Gent M, Blakely JA, Easton JD, et al. The Canadian-American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; 1: 1215-20
114. CAPRIE: Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39
115. Goto S, Salomon DR, Ikeda Y, et al. Characterization of the unique mechanism mediating the shear-dependent binding of soluble von Willebrand factor to platelets. J Biol Chem 1995; 270: 23352-61
116. Coller BS, Anderson K, Weisman HF. New antiplatelet agents: platelet GPIIb/IIIa antagonists. Thromb Haemost 1995; 74: 302-8
117. Garcia JH, Liu KF, Yoshida Y, et al. Influx of leukocytes and platelets in an evolving brain infaret (Wistar rat). Am J Pathol 1994; 144: 188-99
118. Dinarello CA. An update on human interleukin-1: from mulecular biology to clinical relevance. J Clin Immunol 1985; 5: 287-97
119. Hallenbeck JM, Dutka AJ, Tanishima T, et al. Polymorphonuclear leukocyte accumulation in brain regions with low blood flow during the early postischemic period. Stroke 1986; 17: 246-53
120. del Zoppo GJ, Schmid-Schönbein GW, Mori E, et al. Polymorphonuclear leukocytes occlude capillaries following middle cerebral artery occlusion and reperfusion in baboons Stroke 1991; 22: 1276-83
121. Barone FC, Hillegass LM, Tzimas MN, et al. Time-related changes in myeloperoxidase activity and leukotriene by receptor binding reflect leukocyte influx in cerebral focal stroke. Mol Chem Neuropathol 1995; 24: 13-30
122. Dereski MO, Chopp M, Knight RA, et al. Focal cerebral ischemia in the rat: temporal profile of neutrophil responses. Neurosci Res Commun 1992; 11 (3): 179-86
123. Garcia JH, Liu KF, Yoshida Y, et al. Influx of leukocytes and platelets in an evolving brain infaret (Wistar rat). Am J Pathol 1994; 144: 188-99
124. Mori E, Chambers JD, Copeland BR, et al. Inhibition of polymorphonuclear leukocyte adherence suppresses non-reflow after focal cerebral ischemia. Stroke 1992; 23: 712-8
125. Haring H-P, Berg EL, Tsurushita N, et al. E-selectin appears in non-ischemic tissue during experimental focal cerebral ischemia. Stroke 1996; 27: 1386-92
126. Kansas GS, Wood GS, Engelman EG. Maturational and functional diversity of human B lymphocytes delineated with anti-Leu-8. J Immunol 1985; 134: 3003-6
127. Kansas GS, Wood GS, Fishwild DM, et al. Functional characterization of human T lymphocyte subsets distinguished by monoclonal anti-Leu-8. J Immunol 1985; 134: 2995-3002
128. Gallatin WM, Weissman IL, Butcher EC. A cell-surface molecule involved in organ-specific homing of lymphocytes. Nature 1983; 304: 30-4
129. Lewinsohn DM, Bargatze RF, Butcher EC. Leukocyte-endothelial cell recognition: evidence of a common molecular mechanism shared by neutrophils, lymphocytes, and other leukocytes. J Immunol 1987; 138: 4313-21
130. McEver RP. Selectins: novel receptors that mediate leukocyte adhesion during inflammation. Thromb Haemost 1991; 65: 223-8
131. Bevilacqua MP, Nelson RM, Selectins. J Clin Invest 1993; 91: 379-87
132. Wagner DD. Weibel-Palade body: the storage granule for von Willebrand factor and P-selectin. Thromb Haemost 1993; 70: 105-10
133. Patel KD, Zimmerman GA, Prescott SM, et al. Oxygen radicals induce human endothelial cells to express GMP-140 and bind neutrophils. J Cell Biol 1991; 112: 749-59
134. Geng JG, Bevilacqua MP, Moore KL, et al. Rapid neutrophil adhesion to activated endothelium mediated by GMP-140. Nature 1990; 343: 757-60
135. Larson E, Celi A, Gilbert GE, et al. PADGEM protein: a receptor that mediates the interaction of activated platelets with neutrophils and monocytes. Cell 1989; 59: 305-12
136. Palabrica T, Lobb R, Furie BC, et al. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature 1992; 359: 848-51
137. Norman KE, Moore KE, McEver P, et al. Leukocyte rolling in vivo is mediated by P-selectin glycoprotein ligand-1. Blood 1995; 86: 4417-21
138. McEver RP, Moore KL, Cummings RD. Leukocyte trafficking mediated by selectin-carbohydrate interactions. J Biol Chem 1995; 270: 11025-8
139. Bevilacqua MP, Stengelin S, Gembrone Jr MA, et al. Endothelial leukocyte adhesion molecule I: an inducible receptor for neutrophils related to complement regulatory proteins and lectins. Science 1989; 243: 1162-5
140. Haraldsen G, Kvale D, Lien B, et al. Cytokine-regulated expression of E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) in human intestinal microvascular endothelial cells. J Immunol 1996; 156: 2558-65
141. Kansas GS. Selectins and their ligands: current concepts and controversies. Blood 1996; 88: 3259-87
142. Rothlein R, Dustin ML, Marlin SD, et al. A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1. J Immunol 1986; 137: 1270-4
143. Rothlein R, Mainolfi E, Czajkow M, et al. A form of circulating ICAM-1 in human serum. J Immunol 1991; 147: 3788-93
144. Cybulsky MI, Gimbrone MA. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991; 251: 788-91
145. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992; 69: 11-25
146. Carlos T, Kovach N, Schwartz B, et al. Human monocytes bind to two cytokine-induced adhesive ligands on cultured human endothelial cells: endothelial-leukocyte adhesion molecule-1 and vascular cell adhesion molecule-1. Blood 1991; 77: 2266-71
147. Lefkovits J, Plow EF, Topol EJ, Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332: 1553-9
148. Savage B, Bottini E, Ruggeri ZM. Interaction of integrin alpha IIb beta 3 with multiple fibrinogen domains during platelet adhesion. J Biol Chem 1995; 270: 28812-7
149. 3 is selectively expressed on microvessels after focal cerebral ischemia/reperfusion. Stroke 1995; 26: 182
150. 4 during focal cerebral ischemia/reperfusion. Stroke 1997; 28: 858-65
151. Matsuo Y, Onodera H, Shiga Y, et al. Role of cell adhesion molecules in brain injury after transient middle cerebral artery occlusion in the rat. Brain Res 1994; 656: 344-52
152. Matsuo Y, Onodera H, Shiga Y, et al. Correlation between myeloperoxidase-quantified neutrophil accumulation and ischemic brain injury in the rat: effects of neutrophil depletion. Stroke 1994; 25: 1469-75
153. Garcia JH, Liu K-F, Bree MP. Effects of CD11b/18 monoclonal antibody on rats with permanent middle cerebral artery occlusion. Am J Pathol 1996; 148: 241-8
154. Dinarello CA. Biological basis for interleukin-1 in disease. Blood 1996; 87: 2095-147
155. Labriola-Tomkins E, Chandran C, Varnell TA, et al. Structure-function analysis of human IL-1α: identification of residues required for binding to the human type 1 IL-1 receptor. Protein Eng 1993; 6: 535-9
156. Grutter MG, van Oostrum J, Priestle JP, et al. A mutational analysis of receptor binding sites of interleukin-1β: differences in binding of human interleukin-1β muteins to human and mouse receptors. Protein Eng 1994; 7: 663-71
157. Stevenson FT, Torrano F, Locksley RM, et al. Interleukin-1: the patterns of translation and intracellular distribution support alternative secretory mechanisms. J Cell Physiol 1992; 152: 223-31
158. Rubartelli A, Cozzolino F, Talio M, et al. A novel secretory pathway for interleukin-1 beta, a protein lacking a signal sequence. EMBO J 1990; 9: 1503-10
159. Sebire G, Emilie D, Wallon C, et al. In vitro production of 1-6, IL-1 beta, and tumor necrosis factor-alpha by human embryonic microglial and neural cells. J Immunol 1993; 150: 1517-23
160. Bissonnette EY, Enciso JA, Befus AD. Inhibitory effects of sulfasalazine and its metabolites on histamine release and TNF-alpha production by mast cells. J Immunol 1996; 156: 218-23
161. Neta R, Sayers TJ, Openheim JJ. Relationship of TNF to interleukins. Immunol Ser 1992; 56: 499-566
162. Weller A, Isenmann S, Vestweber D. Cloning of the mouse endothelial selectins: expression ot both E-and P-selectin is induced by tumor necrosis factor. J Biol Chem 1992; 267: 15176-83
163. Semenzato G. Tumour necrosis factor: a cytokine with multiple biological activities. Br J Cancer 1990; 61: 354-61
164. Liu T, McDonnell PC, Young PR, et al. Interleukin-1β mRNA expression in ischemic rat cortex. Stroke 1993; 24: 1746-51
165. Wang X, Yue T-L, Barone FC, et al. Concomitant cortical expression of TNF-α and IL-1β mRNA following transient focal ischemia. Mol Chem Neuropathol 1994; 23: 103-14
166. Nawrath PP, Stern DM. Endothelial cells as active participant in procoagulant reactions. In: Gimbrone MA, editor. Vascular endothelium in hemostasis and thrombosis. Edinburgh: Churchill Livingstone, 1986: 31-2
167. Bevilacqua MP, Pober JS, Wheeler ME, et al. Interleukin-1 acts on cultured human vascular endothlium to increase the adhesion of polymorphonuclear leukocytes, monocytes, and related leukocyte cell lines. J Clin Invest 1985; 76: 2003-11
168. Loddick SA, Rothwell NJ. Neuroprotective effects of human recombinant interleukin-1 receptor antagonist in focal cerebral ischaemia in the rat. J Cereb Blood Flow Metab 1996; 16: 932-40.
169. Liu T, Clark RK, McDonnell PC, et al. Tumor necrosis factor-α expression in ischemic neurons. Stroke 1994; 25: 1481-8
170. Garcia JH, Liu K-F, Relton JK. Interleukin-1 receptor antagonist decreases the number of necrotic neurons in rats with middle cerebral artery occlusion. Am J Pathol 1995; 147: 1477-86
171. Gallinaro R, Cheadle WG, Applegate K, et al. The role of the complement system in trauma and infection. Gynecol Obstet 1992; 174: 435-40
172. Mulligan MS, Teh CG, Rudolph AR, et al. Protective effects of CR1 in complement- and neutrophil-mediated tissue injury. J Immunol 1992; 148: 479-85
173. Kaczorowski SL, Schiding JK, Toth CA, et al. Effect of soluble complement receptor-1 on neutrophil accumulation after traumatic brain injury in rats. J Cereb Blood Flow Metab 1995; 15: 860-4
174. Ravingerova T, Slezak J, Tribulova N, et al. High arrythmogenesis during early reperfusion of ischaemic myocardium: participation of oxygen free radicals. J Basic Clin Physiol Pharmacol 1993; 4: 335-46
175. Chan PH. Oxygen radicals in focal cerebral ischemia. Brain Pathol 1994; 4: 59-65
176. Kontos HA, Povlishok JT. Oxygen radicals in brain injury. Cent Nerv Syst Trauma 1986; 3: 257-63
177. Catheart R, Schwiers E, Saul RL, et al. Thymine glycol and thymidine glycol in human and rat urine: a possible assay for oxidative DNA damage. Proc Natl Acad Sci USA 1984; 81: 5633-7
178. Hung TT, Carlson EJ, Leadon SA, et al. Relationship of resistance to oxygen free radicals to CuZn-superoxide dismutase activity in transgenic, transfected and trisomic cells. FASEB J 1992; 6: 903-10
179. Carney JM, Starke-Reed PE, Oliver CN, et al. Reversal of age-related increase in brain protein oxidation decrease in enzyme activity, and loss in temporal and spatial memory by chronic administration of the spin-trapping compound N-tert-butyl-L-phenlnitrone. Proc: Natl Acad Sci USA 1991; 88: 3633-6
180. Watson BD, Ginsberg MD. Ischemic injury in the brain. Role of oxygen radical-mediated processes. Ann NY Acad Sci 1989; 559: 269-81
181. Meister A. Glutalhione metabolism and its selective modification. J Neurochem 1984; 42: 268-74
182. Watson BD, Busto R, Goldberg WJ, et al. Lipid peroxidation in vivo induced by reversible global ischemia in rat brain. J Neurochem 1984; 42: 268-74
183. Copin JC, Ledig M, Tholey G. Free radical scavenging systems of rat astroglial cells in primary culture: effects of anoxia and drug treatment. Neurochem Res 1992; 17: 677-82
184. Daval JL, Ghersi-Egea JF, Oillet J, et al. A simple method for evaluation of superoxide radical production in neural cells under various culture conditions: application to hypoxia. J Cereb Blood Flow Metab 1995; 15: 71-7
185. Matsuo Y, Kihara T, Ikeda M, et al. Role of neutrophils in radical production during ischemia and reperfusion of the rat brain: effect of neutrophil depletion on extracellular ascorbyl radical formation. J Cereb Blood Flow Metah 1995; 15: 941-7
186. Portoles MT, Arahuetes RM, Pagani R. Intracellular calcium alterations and free radical formation evaluated by flow cytometry in endotoxin-treated rat liver Kupffer and endothelial cells. Eur J Cell Biol 1994; 65: 200-5
187. Suematsu M, Kurose I, Asako H, et al. In vivo visualization of oxyradical-dependent photoemission during endothelium-granulocyte interaction in microvascular beds treated with platelet-activating factor. J Biochem 1989; 106: 355-60
188. Kassell NF, Halley EC Jr, Apperson-Hansen C, et al. Randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in Europe, Australia, and New Zealand. J Neurosurg 1996; 84: 221-8
189. Nelson CW, Wei EP, Povlishock JT, et al. Oxygen radicals in cerebral ischemia. Am J Physiol 1992; 263: H1356-62
190. Bradley JR, Johnson DR, Pober JS. Endothelial activation by hydrogen peroxide: selective increases of intercellular adhesion molecule-1 and major histocompatibility complex class I. Am J Pathol 1993; 142: 1598-609
191. Kontos CD, Wei EP, Williams JI, et al. Cytochemical detection of superoxide in cerebral inflammation and ischemia in vivo. Am J Physiol 1992; 263: H1234-42
192. Suematsu M, Schmid-Schönbein GW, Chavez-Chavez RH, et al. In vivo visualization of oxidative changes in microvessels during neutrophil activation. Am J Physiol 1993; 264: H881-91
193. Fujikawa M, Kamiike W, Hatanaka N, et al. Changes in biliary glutathione level during ischemia-reperfusion of rat liver. J Surg Res 1994; 57: 569-73
194. Braughler JM, Hall ED. Central nervous system trauma and stroke: I. Biochemical considerations for oxygen radical formation and lipid peroxidation. Free Radic Biol Med 1989; 6: 289-301
195. Liu TH, Beckman JS, Freeman BA, et al. Polyethylene-glycol-conjugated superoxide dismutase and catalase reduce ischemic brain injury. Am J Physiol 1989; 256: H589-93
196. Traystman RJ, Kirsch JR, Koehler RC. Oxygen radical mechanisms of brain injury following ischemia and reperfusion. J Appl Physiol 1991; 71: 1185-95
197. Yamamoto M, Shima T, Uozumi, et al. A possible role of lipid peroxidation in cellular damage caused by cerebral ischemia and the protective effect of α-tocopherol administration. Stroke 1983; 14: 977-82
198. Zhang X-M, Ellis EF. Superoxide dismutase reduces permeability and edema induced by hypertension in rats. Am J Physiol 1990; 259: H497-503
199. Imaizumi S, Woolworth V, Fishman RA, et al. Liposome-entrapped superoxide dismutase reduces cerebral infarction in cerebral ischemia in rats. Stroke 1990; 21: 1312-7
200. Young B, Runge JW, Waxman KS, et al. Effects of pegorgotein on neurologic outcome of patients with severe head injury: a multicenter, randomized controlled trial. JAMA 1996; 276: 538-43
201. Yang G, Chan PH, Chen J, et al. Human copper-zinc superoxide dismutase transgenic mice are highly resistant to reperfusion injury after focal cerebral ischemia. Stroke 1994; 25: 165-70
202. Xue D, Slivka A, Buchan AM, Tirilazad reduces cortical infarction after transient but not permanent focal cerebral ischemia in rats. Stroke 1992; 23: 894-9
203. Maruki Y, Koehler RC, Kirsch JR, et al. Effect of the 21-aminosteroid tirilazad on cerebral pH and somatosensory evoked potentials after incomplete ischemia. Stroke 1993; 24: 724-30
204. Maruki Y, Koehler RC, Eleff SM, et al. Intracellular pH during reperfusion influences evoked potential recovery after complete ischemia. Stroke 1993; 24: 697-703
205. Haley Jr EC, Kassel NF, Alves WM, et al. Phase II trial of tirilazed in aneurysmal subarachnoid hemorrhage: a report of the Cooperative Aneurysm Study. J Neurosurg 1995; 82: 786-90
206. STIPAS Investigators. Safety study of tirilazad mesylate in patients with acute ischemic stroke (STIPAS). Stroke 1994; 25: 418-23
207. RANTTAS Investigators. A randomized trial of tiriliazad mesylate in patients with acute stroke (RANTTAS). Stroke 1996; 27: 1453-8
208. Peters GR, Hwang L-J, Musch B, et al. Safety and efficacy of 6 mg/kg/day tirilazad mesylate in patients with acute ischemic stroke (TESS Study) [abstract]. Stroke 1996; 27: 195
209. Mori E, Ember J, Copeland BR, et al. Effect of tirilazad mesylate on middle cerebral artery occlusion/reperfusion in non-human primates. Cerebrovasc Dis 1995; 5: 342-9
210. Marshall LF, Marshall SB. Pitfalls and advances from the international tirilazad trial in moderate and severe head injury. J Neurotrauma 1995; 12: 929-32
211. Jennette JC, Falk RJ, Milling DM. Pathogenesis of vasculitis. Semin Neurol 1994; 14: 291-9
212. Sharkey J, Butcher SP. Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral isehaemia. Nature 1994; 371: 336-9
213. Shiga Y, Onodera H, Matsuo Y, et al. Cyclosporin A protects against ischemia-reperfusion injury in the brain. Brain Res 1992; 595: 145-8
214. Graeber MB, Streit WJ, Kreutzberg GW. The third glial cell type, the microglia: cellular markers of activation in situ. Acta Histochem Suppl 1990; 37: 157-60
215. Giulian D, Robertson C. Inhibition of mononuclear phagocytes reduces ischemic injury in the spinal cord. Ann Neurol 1990: 27: 33-42
216. Linnik MD, Zobrist RH, Hatfield MD. Evidence supporting a role for programmed cell death in focal cerebral ischemia in rats. Stroke 1993; 24: 2002-9
217. Siesjö BK. Calcium-mediated processes in neuronal degeneration. Ann NY Acad Sci 1994; 747: 140-61
218. Choi DW. Calcium and excitotoxic neuronal injury. Ann NY Acad Sci 1994; 747: 162-71
219. Triggle DJ. Molecular pharmacology of voltage-gated calcium channels. Ann NY Acad Sci 1994; 747: 267-81
220. Tsien RW, Lipscombe D, Madison DV, et al. Multiple types of neuronal calcium channels and their modulation. Trends Neurosci 1988; 11: 431-8
221. Nakanishi S, Shneider NA, Axel R. A family of glutamate receptor genes: evidence for the formation of heteromultimeric receptors with distinct channel properties. Neuron 1990; 5: 569-81
222. Nakanishi S. Metabotropic glutamate receptors: synaptic transmission, modulation, and plasticity. Neuron 1994; 13: 1031-7
223. Miljanich GP, Ramachandran J. Antagonists of neuronal calcium channels: structure, function, and therapeutic implications. Annu Rev Pharmacol Toxicol 1995; 35: 707-34
224. Muir KW, Lees KR. Clinical experience with excitatory amino acid antagonist drugs. Stroke 1996; 26: 503-13
225. Scriabine A, Schuurman T, Traber J. Pharmacological basis for the use of nimodipine in central nervous system disorders. FASEB J 1989; 3: 1799-806
226. Schmidt JF, Waldemar G. Effect of nimodipine on cerebral blood flow in human volunteers. J Cardiovasc Pharmacol 1990: 16: 568-71
227. Gelmers HJ, Gorter K, De Weerdt C, et al. A controlled trial of nimodipine in acute ischemic stroke. N Engl J Med 1988; 318: 203-7
228. Paci A, Ottaviano P, Trenta A, et al. Nimodipine in acute ischemic stroke: a double-blind controlled study. Acta Neurol Scand 1989; 80: 282-6
229. Mohr JP, Kijanni M, Muschett JL, et al. Nimodipine in acute ischemic stroke [abstract]. Ann Neurol 1989; 26: 124
230. Trust Study Group. Randomized, double-blind, placebo-controlled trial of nimodipine in acute stroke. Lancet 1990; 336: 1205-9
231. Kramer G, Tettenborn B, Rothacker G, et al. Nimodipine German Austrian stroke trial [abstract]. Neurol 1990; 40 Suppl. 1: 415-6
232. American Nimodipine Study Group. Clinical trial of nimodipine in acute ischemic stroke. Stroke 1992; 23: 3-8
233. Martinez-Vila E, Guillen F, Villanueva A, et al. Placebo-controlled trial of nimodipine in the treatment of acute ischemic cerebral infarction. Stroke 1990; 21: 1023-8
234. Bogousslavsky J, Regli F, Zumstein V, et al. Double-blind study of nimodipine in nonsevere stroke. Eur Neurol 1990; 30: 23-30
235. Wimalaratna S, Capildeo R. Nimodipine in acute ischemic stroke [abstract]. J Neurol 1990; 237: 146
236. American Nimodipine Study Group. Clinical trial of nimodipine in acute ischemic stroke. Stroke 1992; 23: 3-8
237. Kaste M, Fogelholm R, Erila T, et al. A randomized, double-blind, placebo-controlled trial of nimodipine in acute ischemic hemispheric stroke. Stroke 1994; 25: 1348-53
238. 2 antagonist, markedly reduces infarct size following middle cerebral artery occlusion in the rat. Neurology 1988; 38: 1667-73
239. Zornow MH, Prough DS. Neuroprotective properties of calcium-channel blockers. New Horiz 1996; 4: 107-14
240. Newcomb R, Palma A. Effects of diverse omega-conopeptides on the in vivo release of glutamic and gamma-aminobutyric acids. Brain Res 1994; 638: 95-102
241. Wu G, Kim HK, Zornow MH. Transient brain ischemia in rabhits: the effect of omega-conopeptide MVIIC on hippocampal excitatory amino acids. Brain Res 1995; 692: 118-22
242. Zhao Q, Smith ML, Siesjö BK. The omega-conopeptide SNX-III, an N-type calcium channel blocker, dramatically ameliorates brain damage due to transient focal ischaemia. Acta Physiol Scand 1994; 150: 459-61
243. Buchan AM, Gertler SZ, Li H, et al. A selective N-type Ca2+ channel blocker prevents CA1 injury 24h following severe forebrain ischemia and reduces infarction following focal ischemia. J Cereb Blood Flow Metab 1994: 14: 903-10
244. Takizawa S, Matsushima K, Fujita H, et al. A selective N-type calcium channel antagonist reduces extracellular glutamate release and infarct volume of local cerebral ischemia. J Cereb Blood Flow Metab 1995; 15: 611-8
245. Desphande JK, Wieloch T. Flunarizine, a calcium entry blocker, ameliorates ischemic brain damage in the rat. Anesthesiology 1986; 64: 215-24
246. 2+ channel blocker and antioxidant, reduces neuronal ischemic injuries. Eur J Pharmacol 1994; 257: 203-10
247. Barone FC, Lysko PG, Price WJ, et al. SB 201823-A antagonizes calcium currents in central neurons and reduces the effects of focal ischemia in rats and mice. Stroke 1995; 26: 1683-90
248. Barone FC, Price WJ, Jakobsen P, et al. Pharmacological profile of a novel neuronal calcium channel blocker includes reduced cerebral damage and neurological deficits in rat focal ischemia. Pharmacol Biochem Behav 1994: 48: 77-85
249. Hossmann KA. Glutamate-mediated injury in focal cerebral ischemia: the excitotoxin hypothesis revised. Brain Pathol 1994; 4: 23-36
250. Seeberg PH. The molecular biology of mammalian glutamate receptor channels. Trends Neurosci 1993; 16: 359-65
251. Choi DW. Methods for antagonizing glutamate neurotoxicity. Cerebrovasc Brain Metab Rev 1990: 2: 105-47
252. Fisher M. Cerestat™ (CNS 1102), a non-competitive NMDA antagonist, in ischemic stroke patients: dose-escalating safety study [abstract]. Cerebrovasc Dis 1994; 4: 245
253. Albers GW. Atkinson RP, Kelley RE, et al. Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Stroke 1995; 26: 254-8
254. Clark WM, Coull BM. Randomized trial of CGS19755, a glutamate antagonist, in acute ischemic stroke treatment [abstract]. Neurology 1994; 44: A270
255. Davis SM. The ASSIST Collaborative Group. Acute stroke studies involving selfotel treatment [abstract]. Stroke 1997; 28: 271
256. Dyker AG, Muir KW, Lees KR. A double-blind, randomised, placebo-controlled, dose-escalation study of remacemide in patients with acute stroke [abstract]. Stroke 1997: 28: 233
257. Warner DS, Martin H, Ludwig P, et al. In vivo models of cerebral ischemia: effects of parenterally administered NMDA receptor glycine site antagonists. J Cereb Blood Flow Metab 1995; 15: 188-96
258. Albers GW, Clark WM, Atkinson RP, et al. Dose escalation study of the NMDA glycine-site antagonist ACEA1021 in acute ischemic stroke [abstract]. Stroke 1997; 28: 233
259. Von Lubitz DK, Lin RC, McKenzie RJ, et al. A novel treatment of global cerebral ischemia with a glycine partial agonist. Eur J Pharmacol 1992; 219: 153-8
260. Fossom LH, Von Lubitz DK, Lin RC, et al. Neuroprotective actions of 1-aminocyclopropanecarboxylic acid (ACPC): a partial agonist at strychnine-insensitive glycine sites. Neurol Res 1995; 17: 265-9
261. Dyker AG, Less KR, Preston C, et al. The safety, tolerability and pharmacokinetics of GV150526A in patients with acute stroke [abstract]. Stroke 1997; 28: 233
262. Carter AJ. Many agents that antagonize the NMDA receptor channel complex in vivo also cause disturbances of motor coordination. J Pharmacol Exp Ther 1994; 269: 573-80
263. Olney JW. Neuroloxicity of NMDA receptor antagonists: an overview. Psychopharmacol Bull 1994; 30: 533-40
264. Muir KW, Lees KR. A randomized, double-blind, placebo-controlled pilot trial of intravenous magnesium sulfate in acute stroke. Stroke 1995; 26: 1183-8
265. Gill R. The pharmacology of α-amino-3-hydroxy-5-methyl-4-isoxazole proprionate (AMPA)/kainate antagonists and their role in cerebral ischemia. Cerebrovasc Brain Metab Rev 1994; 6: 225-56
266. Yatsugi S, Takahashi M, Kawasaki-Yatsugi S, et al. Neuroprotective effect of YM90K, a novel AMPA/kainate receptor antagonist, in focal cerebral ischemia. J Cereb Blood Flow Metab 1996; 16: 959-66
267. Bullock R, Graham DI, Swanson S, et al. Neuroprotective effect of the AMPA receptor antagonist LY293558 in focal cerebral ischemia in the cat. J Cereb Blood Flow Metab 1994; 14: 466-71
268. Browne SE, McCulloch J. AMPA receptor antagonists and local cerebral glucose utilization in the cat. Brain Res 1994; 641: 10-20
269. Graham SH, Chen J, Lan J, et al. Neuroprotective effects of a use-dependent blocker of voltage dependent sodium channels. BW619C89, in rat middle cerebral artery occlusion. J Pharmacol Exp Ther 1994; 269: 854-9
270. Swan JH, Leach MJ. Evaluation of the novel neuroprotective agent BW619C89 in the middle cerebral artery occlusion model of focal ischemia in the spontaneously hypertensive rat and normotensive Fischer 344 rat. Ann NY Acad Sci 1995; 765: 39-46, 59-61
271. Grahamn SH, Chen J, Sharp FR, et al. Limiting ischemic injury by inhibition of excitatory amino acid release. J Cereb Blood Flow Metab 1993; 13: 88-97
272. Lesage AS, De Loore KL, Osikowska-Evers B, et al. Lubeluzole, a novel neuroprotetant, inhibits the glutamate-activated NOS pathway [abstract]. Soc Neurosci 1994; 20: 185
273. Diener HC, Hacke W, Hennerici M, et al. Luheluzole in acute ischemic stroke: a double-blind, placebo-controlled phase II trial. Stroke 1996; 27: 76-81
274. Tecoma ES, Choi DW. GABAergic neocortical neurons are resistant for NMDA receptor-mediated injury. Neurology 1989; 39: 676-82
275. Francis A, Pulsinelli W. The response of GABAergic and cholinergic neurons to transient cerebral ischemia. Brain Res 1982; 243: 271-8
276. Lyden PD, Hedges B. Protective effect of synaptic inhibition during cerebral ischemia. Stroke 1992; 23: 1463-70
277. Lyden PD, Lonzo L. Combination therapy protects ischemic brain in rats: a glutamate antagonist plus a gamma-aminobutyric acid agonist. Stroke 1994; 25: 189-96
278. Sydserff SG, Cross AJ, Green AR. The neuroprotective effect of chlormethiazole on ischaemic neuronal damage following permanent middle cerebral artery in the rat. Neurodegeneration 1995; 4: 323-8
279. Rosenbaum DM, Grotta JC, Pettigrew LC, et al. Baclofen does not protect against cerebral ischemia in rats. Stroke 1990; 21: 138-40
280. Simpson RE, O'Regan MH, Perkins LM, et al. Excitatory transmitter amino acid release from the ischemic rat cerebral cortex: effects of adenosine receptor agonists and antagonists. J Neurochem 1992; 58: 1683-90
281. Olah ME, Stiles GL. Adenosine receptor subtypes: characterization and therapeutic regulation. Annu Rev Pharmacol Toxicol 1995; 35: 581-606
282. Phillis JW. Adenosine in the control of the cerebral circulation. Cerebrovasc Brain Metabl Rev 1989; 1: 26-54
283. Hourani SMO, Cusack NJ. Pharmacological receptors on blood platelets. Pharmacol Rev 1991; 43: 243-98
284. Cronstein B. Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol 1994; 76: 5-13
285. Goldberg MP, Monyer H, Weiss JH, et al. Adenosine reduces cortical neuronal injury induced by oxygen or glucose deprivation in vitro. Neurosci Lett 1988; 89: 323-7
286. Miller LP, Chiang PC, Carrierdo S, et al. The adenosine regulating agent GP-1-668 reduces infarct volume and neurological deficits in a rat model of focal stroke with reperfusion [abstract]. Stroke 1994; 25: 264
287. Bullough DA, Montag A, Zhang C, et al. Adenosine-mediated inhibition of platelet aggregation by acadesine: a novel anti-thrombotic mechanism in vitro and in vivo. J Clin Invest 1994; 94: 1524-32
288. Hamilton AJ, Black PM, Carr DB. Contrasting actions of naloxone in experimental spinal cord trauma and cerebral ischemia: a review. Neurosurgery 1985; 17: 845-9
289. Andrews BT, McIntosh TK, Gonzales MF, et al. Levels of endogenous opioids and effects of an opiate antagonist during regional cerebral ischemia in rats. J Pharmacol Exp Ther 1988; 247: 1248-54
290. Fallis RJ, Fisher M, Lobo RA. A double-blind trial of naloxone in the treatment of acute stroke. Stroke 1984; 15: 627-9
291. Weiss GB, Metabolism and actions of CDP-choline as an endogenous compound and administered exogenously as citicoline. Life Sci 1995; 56: 637-60
292. D'Orlando KJ, Sanadge BW Jr. Citicoline (CDP-choline): mechanisms of action and effects in ischemic brain injury. Neurol Res 1995; 17: 281-4
293. Tazaki Y, Sakai F, Otomo E, et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke 1988; 19: 211-6
294. Goyas JY, Bastard J, Missoum A. Results after 90 days of stroke treatment with CDP-choline, concerning a double-blind test. International Symposium: Brain Suffering and Precursors of Phospholipids; 1980 Jan 18; Paris, 123-8
295. Ping FC, Jenkins LC. Protection of the brain from hypoxia: a review. Can Anaesth Soc J 1978; 25: 468-73
296. 1 on neurologic function, electroencephalogram amplitude, and histology in chronic middle cerebral artery occlusion in cats. Stroke 1988; 19: 1027-35
297. 1 ganglioside treatment of focal ischemia: dose-redose and microdialysis study. J Pharmacol Exp Ther 1993; 265: 24-8
298. 1 ganglioside therapy in acute ischemic stroke. Stroke 1989; 20: 1143-9
299. 1 ganglioside therapy in acute ischemic stroke. Cerebrovasc Dis 1992; 2: 163-8
300. Rocca WA, Dorsey FC, Grigoletto G, et al. Design and baseline results of the monosialoganglioside early stroke trial. Stroke 1992; 23: 519-26
301. 1 in acute ischemic stroke: the SASS Trial. Stroke 1994; 25: 1141-8
302. Izumi N, Yasuda H. A convenient cerebral ischemia model using mice. J Cereb Blood Flow Metab 1983; 3: S391-2
303. Yasuda H, Shuto S, Tsumagari T, et al. Protective effect of a novel imidazole derivative against cerebral anoxia. Arch Int Pharmacodyn Ther 1978; 233: 136-44
304. Yasuda H, Izumi N, Nakanishi M, et al. Brain protection against oxygen deficiency by nizofenone. Adv Exp Med Biol 1988; 222: 403-10
305. Yasuda H, Nakajima A. Brain protection against ischemic injury by nizofenone. Cerebrovasc Brain Metab Rev 1993; 5: 264-76
306. Prehn JH, Welsch M, Backhauss C, et al. Effects of serotonergic drugs in experimental brain ischemia: evidence for a protective role of serotonin in cerebral ischemia. Brain Res 1993; 630: 10-20
307. Fisher M, Meadows ME, Do T, et al. Delayed treatment with intravenous basic fibroblast growth factor reduces infarct size following permanent focal cerebral ischemia in rats. J Cereb Blood Flow Metab 1995; 15: 953-9
308. Koketsu N, Berlove DJ, Moskowitz MA, et al. Pretreatment with intraventricular basic fibroblast growth factor decreases infarct size following focal cerebral ischemia in rats. Ann Neurol 1994; 35: 451-7
309. Gross CE, Bednar MM, Howard DB, et al. Transforming growth factor-beta 1 reduces infarct size after experimental cerebral ischemia in a rabbit model. Stroke 1993; 24: 558-62
310. Cuevas P, Gimenez-Gallego G, Carcellar F, et al. Single topical application of human recombinant basic fibroblast growth factor (rbFGF) promotes neovascularization in rat cerebral cortex. Surg Neurol 1993; 39: 380-4
311. Holtzman DM, Mobley WC. Neutrophic factors and neurologic disease. Neurology 1996; 161: 246-54
312. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-6
313. Garthwaite J, Charles SL, Chess-Williams R. Endothelium-derived relaxing factor release on activation of NMDA receptors suggests a role as intercellular messenger in the brain. Nature 1988; 336: 385-8
314. Dawson VL, Dawson TM, London ED, et al. Nitric oxide mediates glutamate neurotoxicity in primary cortical culture. Proc Natl Acad Sci USA 1991; 88: 6368-71
315. Fukuto JM, Chaudhuri G. Inhibition of constitutive and inducible nitric oxide synthase: potential selective inhibition. Annu Rev Pharmacol Toxicol 1995; 35: 165-94
316. Bredt DS, Hwang PH, Glatt C, et al. Cloned and expressed nitric oxide synthase structurally resembles cytochrome P450 reductase. Nature 1991; 351: 714-8
317. Geller DA, Lowenstein CJ, Shapiro RA, et al. Molecular cloning and expression of inducible nitric oxide synthase from human hepatocytes. Proc Natl Acad Sci USA 1993; 90: 3491-5
318. Grandati M, Verrecchia C, Allix M, et al. NO synthase activities in mice following transient focal cerebral ischemia. In: Krieglstein J, editor. Pharmacology of cerebral ischemia - 1996. Stuttgart: Medpharm Scientific Publishers, 1996: 217-23
319. Huang Z, Huang PL, Panahian N, et al. Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase. Science 1994; 265: 1883-5
320. Huang Z, Huang PL, Ma J, et al. Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-arginine. J Cereb Blood Flow Metab 1996; 16: 981-7
321. Buisson A, Plotkine M, Boulu RG. The neuroprotective effect of a nitric oxide inhibitor in a ral model of focal cerebral ischemia. Br J Pharmacol 1992; 106: 766-7
322. Nagafuji T, Matsui T, Koide T, et al. Blockade of nitric oxide formation by N-omega-L arginine mitigates ischemic brain edema and subsequent cerebral infarction in rats. Neurosci Lett 1992; 147: 159-62
323. Nishikawa T, Kirsch JR, Koehler RC, et al. Effect of nitric oxide synthase inhibition on cerebral blood flow and injury volume during focal ischemia in cats. Stroke 1993; 24: 1717-24
324. Nowicki JP, Duval D, Poignet H, et al. Nitric oxide mediates neuronal death after focal cerebral ischemia in the mouse. Eur J Pharmacol 1991; 204: 339-40
325. Dawson DA, Kusumoto K, Graham KI, et al. Inhibition of nitric oxide synthesis does not reduce infarct volume in a rat model of focal cerebral ischemia. Neurosci Lett 1992; 142: 151-4
326. Yamamoto S, Golanov EV, Berger SB, et al. Inhibition of nitric oxide synthesis increases local ischemic infarction in rat. J Cereb Blood Flow Metab 1992; 12: 717-26
327. Scandinavian Stroke Study Group. A multicenter trial of hemodilution in acute ischemic stroke: I. Results in the total patient population. Stroke 1987; 18: 691-9
328. Italian Acute Stroke Study Group. Hemodilution in acute stroke: results of the Italian Hemodilution Trial. Lancet 1988; 1: 318-21
329. Strand T. Evaluation of long-term outcome and safety after hemodilution therapy in acute ischemic stroke. Stroke 1992; 23: 657-62
330. Goslinga H, Eijzenbach V, Heuvelmans JH, et al. Custom-tailored hemodilution with albumin and crystalloids in acute ischemic stroke. Stroke 1992; 23: 181-8
331. Hsu CY, Norris JW, Hogan EL, et al. Pentoxifylline in acute nonhemorrhagic stroke: a randomized, placebo-controlled, double-blind trial. Stroke 1988; 19: 716-22
332. Fisher M, Prichard JW, Warach S. New magnetic resonance techniques for acute ischemic stroke. JAMA 1995; 274: 908-11
333. Warach S, Gaa J, Siewert B, et al. Acute human stroke studied by whole brain echo planar diffusion-weighted magnetic resonance imaging. Ann Neurol 1995; 37: 231-41
334. Rogvi-Hansen B, Boysen G. Intravenous glycerol treatment of acute stroke: a statistical review. Cerebrovasc Dis 1992; 2: 11-3
335. Bayer AJ, Pathy MS, Newcombe R. Double-blind randomized trial of intravenous glycerol in acute stroke. Lancet 1987; I: 405-8
336. Baker CJ, Onesti ST, Solomon RA. Reduction by delayed hypothermia of cerebral infarction following middle cerebral artery occlusion in the rat: a time-course study. J Neurosurg 1992; 77: 438-44
337. Morikawa E, Ginsberg MD, Dietrich WD, et al. The significance of brain temperature in focal cerebral ischemia: histopathological consequences of middle cerebral artery occlusion in the rat. J Cereb Blood Flow Metab 1992; 12: 380-9
338. Chen H, Chopp M, Zhang ZG, et al. The effect of hypothermia on transient middle cerebral artery occlusion in the rat. J Cereb Blood Flow Melab 1992; 12: 621-8
339. Kil HY, Zhang J, Piantadosi CA. Brain temperature alters hydroxyl radical production during cerebral ischemia/reperfusion in rats. J Cereb Blood Flow Metab 1996; 16: 100-6
340. Rosomoff HL, Holaday DA. Cerebral blood flow and cerebral oxygen consumption during hypothermia. Am J Physiol 1954; 179: 85-8
341. Ginsberg MD, Sternau LL, Globus MY, et al. Therapeutic modulation of brain temperature: relevance to ischemic brain injury. Cerebrovasc Brain Metab Rev 1992; 4: 189-225
342. Warner MA, Neill KH, Nadler JV, et al. Regionally selective effects of NMDA receptor antagonists against ischemic brain damage in the gerbil. J Cereb Blood Flow Metab 1991: 11: 600-10
343. Memezawa H, Zhao Q, Smith ML, et al. Hyperthermia nullifies the ameliorating effect of dizoclipine maleate (MK-801) in focal cerebral ischemia. Brain Res 1995; 670: 48-52
344. Baron JC, von Kummer R, del Zoppo GJ. Treatment of acute ischemic stroke: challenging the concept of a rigid and universal time window [editorial]. Stroke 1995; 26: 2219-21